Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
P&G 160.02 0.83 0.52% -8.91% Sep/05
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Revance Therapeutics traded at $4.67 this Tuesday April 9th, increasing $0.22 or 4.94 percent since the previous trading session. Looking back, over the last four weeks, Revance Therapeutics gained 25.40 percent. Over the last 12 months, its price fell by 85.16 percent. Looking ahead, we forecast Revance Therapeutics to be priced at 4.63 by the end of this quarter and at 4.52 in one year, according to Trading Economics global macro models projections and analysts expectations.